Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash & Current Investments (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Cash & Current Investments for 7 consecutive years, with $78.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 9.1% year-over-year to $78.7 million, compared with a TTM value of $78.7 million through Dec 2025, up 9.1%, and an annual FY2025 reading of $78.7 million, up 9.1% over the prior year.
  • Cash & Current Investments was $78.7 million for Q4 2025 at aTYR PHARMA, up from $6.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $116.4 million in Q3 2021 and bottomed at $6.1 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $80.8 million, with a median of $79.5 million recorded in 2025.
  • The sharpest move saw Cash & Current Investments skyrocketed 240.53% in 2021, then tumbled 90.68% in 2025.
  • Year by year, Cash & Current Investments stood at $107.9 million in 2021, then crashed by 38.7% to $66.1 million in 2022, then soared by 48.41% to $98.2 million in 2023, then decreased by 26.53% to $72.1 million in 2024, then grew by 9.1% to $78.7 million in 2025.
  • Business Quant data shows Cash & Current Investments for ATYR at $78.7 million in Q4 2025, $6.1 million in Q3 2025, and $80.3 million in Q2 2025.